

Index

Page numbers followed by 'f' indicate figures; page numbers followed by 't' indicate tables.

- 3PPP, 134f
- AAADC (aromatic amino acid decarboxylase), 97, 98f
- ABT089, 203
- acetylcholine (ACh),
 in arousal pathways, 150, 152f
 and blocked dopamine receptors, 93f
 overactivity, 95
 reciprocal relationship with dopamine, 92f
- acetylcholine-linked mechanisms, 202
- ACP 103, 200
- ACP-104, 129, 134f
- ACR16, 134f
- adipose tissue, insulin resistance in, 141, 144f
- adolescence
 aggressiveness in, 179
 removal of synaptic connections, 68
 risperidone for treating psychotic disorders, 166
- affective blunting, 5
- affective flattening, as SSRI side effect, 110
- affective symptoms
 dorsal vs. ventral regulation, 76f
 mesolimbic dopamine pathway role in, 28
 multiple disorders impacting, 15f
 pharmacy, 182, 184f
 in schizophrenia, shared with other disorders, 14
- aggressive symptom pharmacy, 181f
- aggressiveness, 10
 multiple disorders impacting, 15f, 16f
 in schizophrenic patients, 13
- agitation,
 benzodiazepines for, 188
 and receptor conformation, 132f
- agranulocytosis, clozapine and, 164
- akathisia
 from aripiprazole, 175
 nigrostriatal pathway dopamine deficiencies and, 31
- alanine-serine-cysteine transporter (ASC-T), glial, 34
- alogia, 5, 6t
- alpha 1 adrenergic receptors
 atypical antipsychotic agents and, 139f
 and sedation, 151f
- alpha-1 receptor, antagonism, 94f
- alpha-2 adrenergic receptors, atypical antipsychotic agents and, 139f
- alpha 2 antagonists, 168
- alpha-4 beta-2 nicotinic acetylcholine receptor, 203
- alpha-7-nicotinic cholinergic agonists, 202
- alpha amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, 40, 40f, 66f
 synapses with, 67f
- Alzheimer's disease, 180
 cognitive symptoms, 13
 excitotoxicity and, 56, 57f
 symptoms shared with schizophrenia, 12, 13, 13f
- amantadine, 194
- amenorrhea, 32, 90
- d-amino acid oxidase (DAO), 38f, 39

- amisulpride, 130, 134*f*, 135*f*, 176, 183
 - and cardiometabolic risk, 140*t*
 - clinical actions of, 125
 - and diabetes, 171
 - for negative symptoms in schizophrenia, 182*f*
 - pharmacological icon, 177*f*
 - and QTc prolongation, 171
- amoxapine (Asendin), 173, 174*f*
- AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole-priopionic acid) glutamate receptors, 64
 - and synaptogenesis, 62
- AMPA-kines, 199
- amphetamines, 44
 - and dopamine release, 26
 - response to emotional input, 78
 - and schizophrenia symptoms, 75, 77*f*
- amylin, 204
- anhedonia, 5, 6*t*, 30
- antagonists,
 - vs. inverse agonist, 105
 - vs. partial agonists, 132*f*
 - presynaptic, 199*f*
- anticholinergic agents
 - D2 antagonism and, 93*f*
 - side effects, 95
- antihistamines, 82
 - atypical, 96
 - administration frequency, 122
 - cardiometabolic risk and, 140*t*
 - cardiometabolic risk management, 145
 - hit-and-run receptor binding properties, 124*f*
 - hypothetical action over time, 125*f*
 - to improve schizophrenia symptoms, 109
 - pharmacological properties, 139*f*
 - and prolactin, 118*f*
 - properties, 119, 135*f*
 - and weight gain risk, 140*t*
 - avoiding sedation and enhancing long-term outcome, 155*f*
 - benzodiazepines to lead in or top off, 188*f*
 - best practices for monitoring and managing, 149*f*
 - cardiometabolic risk and, 137–150
 - combining two, 191
 - conventional, 91*f*
 - vs. atypical, 112*f*, 114*f*
 - D2 binding of, 123*f*
 - D2-receptor antagonist, 83
 - hypothetical action over time, 123*f*
 - muscarinic cholinergic blocking properties, 91, 95
 - pharmacological properties, 82–96
 - and prolactin, 118*f*
 - risk and benefits of long-term, 95
 - in use, 85*t*
 - as D2 dopamine receptor blockers, 27
 - first-generation, 83*f*, 96
 - high doses, 191*f*
 - links between binding properties and clinical actions, 136
 - low-potency, and dissociation, 124
 - “off-label” uses, 82
 - patient toleration of, 163
 - pharmacokinetics, 156–162
 - pharmacological properties, 162–179
 - prescribing information, 82
 - prophylactic, 192
 - receptor interactions for, 134
 - sedation as short-term tool, 152*f*
 - side effects and compliance, 153*f*
 - switching, 185, 187*f*
 - process to avoid, 187*f*
 - from sedating to nonsedating, 189*f*
- antisocial personality disorder, 13
- anxiety disorders
 - 5HT1A receptors and, 103*f*
 - quetiapine for, 168*f*
- anxious mood, 14
- anxious self-punishment, 3
- apathy, 3
 - histamine-1 with 5HT2C antagonism, 141*f*
- aripiprazole, 129, 130, 134*f*–136*f*, 158, 175, 183
 - and cardiometabolic risk, 140*t*
 - as CYP 2D6 substrate, 158, 159*f*
 - and diabetes, 171
 - dosage with carbamazepine, 161*f*, 162
 - pharmacological icon, 176*f*
 - raising levels of, 160*f*
 - and sedation, 184, 186*f*
 - switching from sedating agent to, 189
 - and weight gain risk, 140*t*
- aromatic amino acid decarboxylase (AAADC), 97, 98*f*
- asenapine, 122*f*, 200
- Asendin (amoxapine), 173, 174*f*
- asociality, 5, 6*t*
- assaultiveness, 10
- atorvastatin
 - impaired, in schizophrenia, 11
- attention deficit hyperactivity disorder (ADHD), 180
 - symptoms shared with schizophrenia, 14
- attitudes, hostile, 3
- atypical antipsychotic agents, 96
 - administration frequency, 122
 - cardiometabolic risk and, 140*t*

- cardiometabolic risk management, 145
- clozapine as, 163
- vs. conventional, 112*f*, 114*f*
- hit-and-run receptor binding properties, 124*f*
- hypothetical action over time, 125*f*
- properties, 119, 139*f*
- and weight gain risk, 140*t*
- auditory hallucinations, 5
- autism, 180
 - cognitive symptoms, 13
 - irritability in children with, 181
 - risperidone for irritability, 166
- avolution, 5, 6*t*
- “awakening”, 164, 191
- benzamide antipsychotics, clinical actions of, 125
- benzodiazepines, 153, 155*f*, 180
 - for aggression management, 181*f*
 - for agitation, 188
 - injectable, 179
 - to lead in or top off antipsychotics, 188*f*
 - when switching antipsychotics, 189*f*
- bifeprunox (DU 127090), 129, 130, 134*f*–136*f*, 177
 - and cardiometabolic risk, 140*t*
 - and diabetes, 171
 - in metabolic pharmacy, 183
 - metabolized by CYP 3A4, 158
 - for obesity, 202
 - pharmacological icon, 178*f*
 - and sedation, 186*f*
 - sedation risk with, 184
- bipolar disorder. *See also* mood stabilizers
 - bifeprunox for treating, 178
 - depressed phase of, 169
 - olanzapine and, 165
 - risperidone effectiveness for, 167
 - symptoms shared with schizophrenia, 12, 13, 13*f*
 - ziprasidone for, 170
- blame, 3
- blonanserin, 122*f*
- blood pressure
 - monitoring, 146, 150*f*
- blunted affect, 6*t*
- blurred vision, from conventional antipsychotics, 92*f*
- BMJ-14802, 200
- body mass index (BMI), 142*f*
 - baseline measurement, 149*f*
 - monitoring, 150*f*
- borderline personality disorder, 13, 180
- brain. *See also* circuits
 - dopamine pathways in, 26*f*; 22–29
 - excitotoxicity in early development, 62*f*
 - insult and schizophrenia, 57
 - survival of wrong neurons, 59
 - focus on malfunctioning areas, 16
 - glutamate pathways in, 43*f*; 41–45
 - nucleus accumbens as pleasure center, 83
 - brain circuits, and schizophrenia symptoms, 14
 - brain damage, 180
 - brain-derived neurotrophic factor (BDNF), 58
 - 5HT6 receptors and, 201
 - genes coding for, 63*f*
 - and long-term memory formation, 99
 - and synapse formation, 62, 65*f*
- Brief Psychiatric Rating Scale, 7*t*
- burnout
 - of neuronal systems, 28
 - in schizophrenic patients, 54, 55*f*
- bupirone, 201
- calcium
 - excessive
 - and excitotoxicity, 58*f*
 - overexcitation and dangerous opening of, 55
- calcyon, genes for, 73*f*
- cannabinoid antagonists, 203
- carbamazepine (Equetro), 160
 - CYP450 3A4 and discontinuation, 162*f*
 - CYP450 3A4 induced by, 161*f*
 - antipsychotic agents and, 143*f*; 171
 - atypical antipsychotic agents and, 139, 140*t*
 - clozapine and, 164
 - low risk antipsychotic agents, 140*t*
 - olanzapine and, 165
 - receptors mediating, 139*f*
- cardiovascular disease
 - atypical antipsychotic agents and, 137
 - risk of, 142*f*
- cardiovascular side effects, of antipsychotic drugs, 95
- catabolic enzymes,
 - and dopamine breakdown, 21, 21*f*
 - and dorsolateral prefrontal cortex, 19*f*
 - genes for, 73*f*
- CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness), 153*f*
- cerebral cortex,
 - antipsychotic agent binding to postsynaptic 5HT2A receptors, 114*f*
 - aggressiveness in, 179
 - psychotic illness, symptoms shared with schizophrenia, 12, 13, 13*f*
 - risperidone for, 166

- chlorpromazine (Thorazine), 82, 85*t*
 cholecystokinin (CCK), 204
 chorea, dopamine hyperactivity in nigrostriatal pathway and, 31
 CHRNA (alpha-7 nicotinic cholinergic receptor), 72*f*
 circadian rhythms
 5HT7 receptors and, 103*f*
 CI1007, 134*f*
 Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), 153*f*
 clinical practice
 vs. clinical trials, 178
 symptom treatment, vs. disease treatment, 179
 Clopixol (zuclopenthixol), 85*t*
 clozapine, 136*f*, 157, 157*f*, 158, 184
 5HT6-antagonist properties of, 201
 for affective symptoms in schizophrenia, 183
 for aggression management, 180, 181*f*
 and antagonism of muscarinic cholinergic receptor, 146*f*
 augmenting, 191
 binding properties, 163*f*
 and cardiometabolic risk, 140*t*
 as CYP 2D6 substrate, 158, 159*f*
 dosage with carbamazepine, 161*f*, 162
 M3 receptors blocked by, 146*f*
 for negative symptoms in schizophrenia, 182*f*
 pharmacological icon, 163*f*
 pharmacological properties, 163
 potency, and dissociation, 124
 raising levels of, 160*f*
 rebound psychosis from discontinued, 185
 for sedation, 185
 for suicide reduction, 164, 184*f*
 for symptom reduction in psychosis, 179
 and weight gain risk, 140*t*
 cocaine,
 and dopamine release, 26
 as antipsychotic side effect, 95
 from conventional antipsychotics, 92*f*
 as SSRI side effect, 110
 cognitive functioning,
 5HT1A receptors and, 103*f*
 5HT2C receptors and, 103*f*
 dorsolateral prefrontal cortex (DLPFC) and, 18*f*, 27
 impaired, 153
 sedation and somnolence and, 154
 mesocortical prefrontal cortex and, 17*f*
 quantifying, 11
 in schizophrenia, shared with other disorders, 13, 14*f*
 serotonin receptors and, 99
 cognitive symptom pharmacy, 182, 183*f*
 “combos” (combination of medications)
 for schizophrenia, 190, 204
 for symptom reduction in psychosis, 179
 communication
 dysfunction of, 5
 inhibitors, 202
 conceptual disorganization, 3
 conduct disorder, 179
 connectivity, genes affecting, 58
 constipation
 from conventional antipsychotics, 92*f*
 and emotion and cognitive symptoms, 17*f*
 and schizophrenia symptoms, 15
 cortical arousal, neurotransmitters of, 152*f*
 cortical brainstem glutamate projection, 43*f*, 44*f*
 cortical pyramidal neurons
 inhibition by 5HT1A receptors, 103*f*
 cortico-striatal-thalamic-cortical (CSTC)
 loops, 46, 47*f*
 corticoaccumbens projections, NMDA
 glutamate receptor hypofunction in, 51*f*
 corticobrainstem glutamate pathways
 neurons, 45
 and NMDA receptor hypofunction
 hypothesis of schizophrenia, 42–45
 corticocortical glutamate pathways, 43*f*, 48–52
 NMDA receptor regulation of, 53*f*
 corticostriatal glutamate pathways, 43*f*, 46
 corticothalamic glutamate pathways, 43*f*, 46
 cross titration, 186, 187*f*
 getting caught in, 188*f*
 CX516, 199
 CX546, 200
 CX619/Org 24448, 200
 cyamemazine (Tercian), 85*t*, 96, 175
 pharmacological icon, 175*f*
 cyclic AMP (adenosine monophosphate),
 disruptions in, 70*f*
 d-cycloserine, 195, 197, 197*f*
 cytochrome P450 (CYP450) enzyme systems,
 156, 156*f*
 CYP450 1A2 substrates, 157, 157*f*
 and smoking, 158, 158*f*
 CYP450 2C9, 158
 CYP450 2C19, 157
 CYP450 2D6, 157, 158, 159*f*
 antidepressants as inhibitors, 160*f*
 genetic polymorphism for, 157, 157*f*

- in risperidone conversion to paliperidone, 159*f*, 160*f*
 - inhibitors, 161*f*
 - CYP450 3A4, 158
 - inducers, 160
 - types, 156
- d-amino acid oxidase activator (DAOA), 69*f*
 - and NMDA receptor regulation, 68, 68*f*
- d-amino acid oxidase (DAO), 68, 69*f*
- DDC (DOPA decarboxylase), 20, 20*f*
- death. *See also* neurons, cell death
 - premature
 - atypical antipsychotic agents and, 137
 - risk of, 142*f*
- delusions, 2, 4
 - antipsychotic action to reduce, 179
 - mesolimbic dopamine pathway role in, 26
 - reduction with mesolimbic D2 receptor block, 90
- dementia. *See also* Alzheimer's disease
 - behavioral disturbances, 181
 - poststroke, cognitive symptoms, 13
 - psychosis with, 166
 - symptoms shared with schizophrenia, 12, 13*f*
 - excitotoxicity for pruning, 56
- Depixol (flupenthixol), 85*t*
- depressed mood, 14
 - 5HT1A receptors and, 103*f*
- depressive psychosis, 3
- diabetes mellitus,
 - atypical antipsychotic agents and, 137
 - zotepine and, 172
- diabetic ketoacidosis (DKA), 143, 147*f*, 149*f*
 - clozapine and, 164
 - olanzapine and, 165
 - risperidone and, 167
- 3-[(2, 4-dimethoxy) benzylidene] anabaseine (DMXB-A), 203
- DISC-1 (disrupted in schizophrenia-1), 59, 61, 64*f*
 - genes for, 63*f*, 70*f*
 - and glutamate synapses strengthening, 62, 66*f*
 - and NMDA receptor regulation, 68*f*
 - and NMDA regulation, 71
 - and synapse formation, 62, 65*f*
 - and synaptic vesicle transport, 71
- disinhibition, 100
- disorganized/excited psychosis, 3
- disorientation, 3
- divalproex (Depakote),
 - for schizophrenia, 190
 - adding to antipsychotic, 191*f*
- divine mission, 3
- DMXB-A {3-[(2, 4-dimethoxy) benzylidene] anabaseine}, 203
- Dolmatil (sulpiride), 85*t*, 96, 129, 130, 134*f*, 135*f*, 177
 - clinical actions of, 125
 - pharmacological icon, 177*f*
- dopa decarboxylase (DDC), 20, 20*f*
- dopamine, 18, 72*f*
 - 5HT2A antagonists stimulation of release, 105
 - and acetylcholine activity, 93*f*
 - acetylcholine release inhibition, 94
 - agonist actions at 5HT1A receptors and, 131
 - in arousal pathways, 150
 - brain pathways, 26*f*, 22–29
 - deficit in mesocortical projections to dorsolateral prefrontal cortex, 28
 - diverse levels in brain subsections, 29
 - dorsolateral prefrontal cortex regulation by, 19*f*
 - genes influencing, 19*f*
 - hit-and-run theory, 127*f*
 - interaction with serotonin, in nigrostriatal dopamine pathway, 107*f*, 111*f*
 - levels in untreated schizophrenia, 127*f*
 - neuronal tuning, 29
 - neurotransmission spectrum, 128*f*
 - untreated schizophrenia and after serotonin dopamine antagonist, 120*f*
 - pharmacologic mechanisms influencing, 19*f*
 - prolactin inhibition by, 117*f*
 - reciprocal relationship with acetylcholine, 92*f*
 - 5HT1A and 5HT2A receptor regulation, 99, 100
 - 5HT2C receptors and, 103*f*
 - serotonin inhibition of, 106*f*
 - serotonin receptors influence on, 105*f*
 - serotonin regulation of, 108*f*–110*f*
 - synthesis, 20*f*
 - termination of action, 21*f*
 - and thalamic filter, 48*f*
 - tuning output with serotonin 2A/dopamine-2 antagonists, 119
- dopamine D1-selective agonists, 202
- dopamine D2 partial agonists, 96, 128*f*, 129, 129*f*
 - aripiprazole as, 175
- dopamine D2 receptor agonists, 128*f*, 129
- dopamine D2 receptors, 21
 - antagonists, 83, 83*f*, 84*f*, 91, 96, 129
 - and anticholinergic agents, 93*f*
 - integrated theory of schizophrenia and, 88*f*
 - mesocortical dopamine pathway and, 85*f*
 - nigrostriatal dopamine pathway and, 86*f*

- dopamine D2 receptors, (*Contd.*)
 rapid dissociation of 122*f*
 tuberoinfundibular dopamine pathway and, 88*f*
 blockade in nucleus accumbens, 107
 continuous occupancy, 169
 conventional antipsychotic binding to, 119
 dilemma of blocking in all dopamine pathways, 90
 output, 129*f*
 presynaptic, 21, 23*f*, 24*f*
 rapid dissociation from, 119, 121
 side effects of unwanted blockade, 136
 somatodendritic, 25*f*
- dopamine D3 antagonists, 202
- “dopamine hypothesis of schizophrenia”, 27
- dopamine neurons, 105
- dopamine partial agonists (DPAs), 125, 127*f*, 180*f*
 for aggression management, 181*f*
 for cognitive function improvement, 182*f*
 in development, 134*f*
 development of new, 202
 for first-line treatment of schizophrenia
 positive symptoms, 179
 integrated theory of schizophrenia and, 132*f*
 on market, 134*f*
 in mesolimbic pathway, 130*f*
 for negative symptoms in schizophrenia, 182*f*
 and nigrostriatal pathway, 131*f*
 spectrum, 135*f*
 switching from SDA to, 190*f*
- dopamine receptors, 21, 22*f*
- dopamine transporter (DAT), 20, 21*f*, 22*f*
 and dorsolateral prefrontal cortex, 19*f*
- dopaminergic neurons, 20–22
 cognitive regulation by, 27
 cognitive symptoms and, 18*f*
 dopamine deficit in mesocortical projections to, 28
 genes influencing, 19*f*
 information processing involving, 73
 mesocortical dopamine pathway, 29*f*
 mesolimbic dopamine pathways in schizophrenia, 85*f*
 regulation by dopamine and serotonin, 19*f*
 and schizophrenia symptoms, 15, 76*f*
 from histamine-1 receptor blockade, 95
- drug abuse, 179
 by schizophrenic patients, 90
 symptoms shared with schizophrenia, 13
- drug-induced parkinsonism, 86
- drug-induced psychoses, symptoms shared with schizophrenia, 12
- drug interactions, 162
- dry mouth
 from conventional antipsychotics, 92*f*
- dysbindin, 59
 genes coding for, 63*f*
 and glutamate synapses strengthening, 62, 66*f*
 and NMDA receptor regulation, 68*f*
 and NMDA regulation, 71
 and synapse formation, 62, 65*f*
 vGluT regulated by, 71
- dysconnectivity, 59
- dyskinesias, dopamine hyperactivity in nigrostriatal pathway and, 31, 32*f*
- dyslipidemia, 139
 aripiprazole and, 176
 atypical antipsychotic agents and, 137
 blood pressure monitoring, 146
 ziprasidone and, 171
 zotepine and, 172
- dystonia, nigrostriatal pathway dopamine deficiencies and, 31
- dystrobrevin-binding protein 1, 58
- efficacy, path to, 155*f*
- efficacy profile, 154*f*
- elderly
 risperidone for, 166
- EMD128130 (sarizotan), 134*f*, 202
- emotion
 amygdala response to input, 78
 brain component regulating, 16
 mesocortical prefrontal cortex and, 17*f*
 mesolimbic dopamine pathway role in, 28
 brain areas impacting, 75
- eplivanserin (SR 46349), 201
- ERB signaling system, neuregulin activation of, 71
- essential amino acids, 39
- Essential Psychopharmacology: The Prescriber's Guide* (Stahl), 162, 163
- excitatory amino acid transporters (EAAT), 33, 40*f*
 for glutamate uptake, 35*f*
- “excitotoxic hypothesis of schizophrenia”, 54
- excitotoxicity, 57*f*
 cellular events during, 58*f*–61*f*
 in early fetal brain development, 62*f*
 and glutamate systems, 55, 194
 and neuronal insult, 57
- executive dysfunction, 11
 impaired
 in schizophrenia, 11
 by mesocortical dopamine pathway, 27

- extrapyramidal symptoms (EPS), 121, 123*f*
 - 5HT_{2A} antagonist to reduce, 105, 107
 - absence with atypical antipsychotics, 125*f*
 - D₂ receptor blockage and, 86
 - dopamine partial agonism and, 132*f*
 - risperidone and, 166
 - from unwanted D₂ receptor blockade, 136
- fasting triglycerides
 - antipsychotic agents and, 145*f*
 - baseline measurement, 145, 149*f*
 - monitoring, 150*f*
 - quetiapine and, 169
 - rapid elevation of, 141
 - risperidone and, 167
 - ziprasidone and, 171
- fear. *See also* anxiety disorders
 - processing by amygdala, 77*f*
 - excitotoxicity in early development, 62*f*
 - insult and schizophrenia, 57
 - survival of wrong neurons, 59
 - insults in neurodegenerative theories of schizophrenia, 54*f*
- first-generation antipsychotic agents, 83*f*, 96
- fluoxetine (Prozac),
 - metabolite of, 159
 - olanzapine and, 165
- flupenthixol (Depixol), 85*t*
- fluphenazine (Prolixin), 85*t*
- fluvoxamine, 159, 200
- free radicals, 60*f*
 - and neuron death, 56
 - scavengers for excitotoxicity, 196*f*
- G protein-linked receptors, 103*f*
- GABA (gamma-aminobutyric acid), 44*f*, 72*f*
- GABA (gamma-aminobutyric acid) neurons, 46, 47*f*
 - for connecting serotonin and dopamine neurons, 105
 - dopamine impact on, 48*f*
 - release, 105*f*
- galactorrhea, 32, 90
- genes
 - susceptibility, 58
 - for schizophrenia, 63*t*, 73
- genetic programming, in neurodegenerative theories of schizophrenia, 54*f*
- glial alanine-serine-cysteine transporter (ASC-T), 34
 - glutamine release from, 36*f*
 - glycine from, 38
- glial d-serine transporter, 38*f*
- glial SNAT, 34, 36*f*, 38
- glucose
 - monitoring fasting, 146
 - agonist actions at 5HT_{1A} receptors and, 131
 - conversion to glutamine, 34, 35*f*
 - system overactivity, 28, 55
 - key pathways in brain, 43*f*, 41–45
 - NMDA hypofunction hypothesis of schizophrenia and, 42–45
 - NMDA receptor excitation spectrum by, 57*f*
 - pharmacology, 194
 - preventing release, 199*f*
 - recycled and regenerated, 35*f*
 - conversion to glutamine, 36*f*
 - glutamine release from glial cells, 36*f*
 - 5HT_{1A} and 5HT_{2A} receptor effect, 115*f*
 - regulation with 5HT_{1A}, 113, 116
 - role in schizophrenia pathophysiology, 33
 - susceptibility gene effect on, 71
 - synapses, convergence of susceptibility genes for schizophrenia on, 68
 - synthesis, 33
- glutamate receptors, 39, 40*f*
 - metabotropic, 39, 42*f*
 - types, 41*t*
- glutamatergic corticostriatal projections,
 - NMDA glutamate receptor hypofunction in, 51*f*
- glutaminase, 34, 36*f*
- glutamine
 - glutamate conversion to, 34, 35*f*
 - release from glial cells, 36*f*
- glutamine synthetase, 34
- glycine, 197, 197*f*
 - from glial cells, 38
 - from l-serine, 39
 - production, 37
- glycine agonists, 195
- glycine transporters (GlyT1), 196
 - inhibitors, 198*f*
- grandiose expansiveness, 3
- guilt, 14
 - CYP450 enzymes in wall, 156
- GW742457, 201
- H₁ histamine receptor, and weight gain, 137
- hallucinations, 2, 5
 - 5HT_{2A} receptors and, 103*f*
 - 5HT_{2A} receptors effect on glutamate release and, 113
 - antipsychotic action to reduce, 179
 - mesolimbic dopamine pathway role in, 26

- hallucinations (*Contd.*)
 reduction with mesolimbic D2 receptor
 block, 90
 serotonin receptors and, 99
 voices in, 2
- haloperidol (Haldol), 85*t*, 91*f*, 95
- histamine,
 in arousal pathways, 150, 152*f*
 antagonism, 94*f*
 atypical antipsychotic agents and, 139*f*
 blockade of, 95
 and sedation, 151*f*
- histamine-1, with serotonin-2C antagonist, and
 appetite stimulation, 141*f*
- "hit and run" binding, 121
- hostile belligerence, 3
- hydroxy-pyruvate (OH-pyruvate), 38*f*, 39, 69*f*
- 9-hydroxy-risperidone, 167. *See also*
 paliperidone
- 5-hydroxytryptophan (5HTP), 97, 98*f*
 of mesolimbic dopamine pathway, 27
- hyperglycemic hyperosmolar syndrome (HHS),
 143, 147*f*, 149*f*
 clozapine and, 164
 olanzapine and, 165
 risperidone and, 167
- hyperinsulinemia, 137
- hyperprolactinemia, 90
 5HT2A antagonists and reduction of, 116
 from unwanted D2 receptor blockade, 136
- hypothalamic nuclei,
 dopamine pathway from, 26*f*, 33
- iloperidone, 122*f*, 200
- impulsivity, 13
 NMDA receptor hypofunction affect, 46
 schizophrenia and, 11, 73, 74*f*
- insomnia,
 quetiapine for treating, 169
- insulin, blocking M3-cholinergic receptors to
 reduce, 146*f*
- insulin resistance, 139
 atypical antipsychotic agents and, 144*f*, 149*f*
 psychopharmacologist options for, 151*f*
 quetiapine and, 169
 risperidone and, 167
 ziprasidone and, 171
 zotepine and, 172
- integrated dopamine hypothesis of
 schizophrenia, 33, 35*f*
- interpersonal functioning, impaired, in
 schizophrenia, 78
- inverse agonists,
 vs. antagonists, 105
- ion channel-linked receptors, 40
- ionotropic receptors, 40
- irritability, 14
- judgment, distortions in schizophrenia, 78
- kainite receptors, 40, 40*f*
 and schizophrenia symptoms, 43, 194
- ketoconazole, 159
- lactation, 32
 for schizophrenia, 190
 adding to antipsychotic, 191*f*
- language, odd use of, 11
- lazaroids, as free radical scavenger, 196*f*
- life expectancy, of schizophrenic patients, 4
- ligand-gated ion channels, 40*f*
- lithium, 190
 for affective symptoms in schizophrenia, 183
 for suicide reduction, 183, 184*f*
- liver
 CYP450 enzymes in, 156
 insulin resistance in, 141, 144*f*
- long-term potentiation (LTP), 62, 66*f*
- low-potency antipsychotic agents, and
 dissociation, 124
- loxapine (Loxitane), 85*t*, 96
 5HT6-antagonist properties of, 201
 pharmacological icon, 174*f*
- luxapine, 173
- LY 293558, 200
- "master switch", 41
- MDL 100907, 201
- Mellaril (thioridazine), 85*t*
- MEM3454, 203
- memantine, 194
- memory,
 long-term formation,
 BDNF and, 99
- mental retardation, 180
- mesocortical dopamine neurons, 45
- mesocortical dopamine pathway, 26*f*, 27, 29*f*
 and D2 antagonists, 85*f*
 dopamine output and, 120*f*, 132*f*
 and serotonin-dopamine antagonism, 113*f*
 to ventromedial prefrontal cortex, 30*f*
- mesocortical prefrontal cortex
 and emotion and cognitive symptoms, 17*f*
 and schizophrenia symptoms, 15
- mesolimbic circuits
 malfunctioning, and positive symptoms of
 schizophrenia, 15, 16
 and positive symptoms of schizophrenia, 17*f*

- mesolimbic dopamine hypothesis, 28*f*
 mesolimbic dopamine pathway, 26, 26*f*, 27*f*, 29, 44*f*
 blockade of D2 receptor antagonists, 84, 84*f*, 91
 blockade of D2 receptors, 83
 dopamine output and, 120*f*, 132*f*
 hyperactivity of, 35*f*
 and thalamus, 51*f*
 mesolimbic pathway, dopamine partial agonist in, 130*f*
 mesoridazine (Serentil), 85*t*
 metabolic highway, 142*f*
 monitoring on, 149*f*, 150*f*
 metabolic pharmacy, 183, 185*f*
 metabotropic glutamate receptors (mGluRs), 39, 42*f*, 197
 mGluRs (metabotropic glutamate receptors), 39, 42*f*, 197
 mirtazapine, 200
 mitochondria, 61*f*
 modafinil, 202
 molindone (Moban), 85*t*
 monoamine oxidase (MAO),
 and dopamine breakdown, 21, 21*f*
 5HT_{2C} receptors and, 103*f*
 serotonin receptors and, 99
 mood stabilizers, 160, 180. *See also* lithium
 for aggression management, 181*f*
 for schizophrenia, 190
 adding to antipsychotic, 191*f*
 mesolimbic dopamine pathway role in, 26
 reduction in, 5, 30
 motor activity
 as antipsychotic side effect, 95
 disturbances, 2
 dopamine and prevention of side effects, 124
 nigrostriatal dopamine pathway to control, 31
 muscarinic-1 agonists, 203
 muscarinic-1 receptors
 atypical antipsychotic agents and, 139*f*
 and sedation, 151*f*
 muscarinic 3 (M3) antagonism, and
 antipsychotic agents, 147*f*
 muscarinic cholinergic receptors,
 antagonism of, 144
 blockade from conventional antipsychotics, 92*f*, 91–95
 blocking to reduce insulin release, 146*f*
 antipsychotic agents and, 171
 myocarditis, clozapine and, 164
 n-back test, 74*f*
 in schizophrenia, 75*f*
 N-methyl-d-aspartate (NMDA) glutamate
 system, development abnormalities, 28
 N-methyl-glycine, 196
 N-methyl loxapine, 173
 Navane (thiothixene), 85*t*
 nefazodone, 159
 Negative Symptom Assessment, 7*t*
 negative symptom pharmacy, 181, 182*f*
 nemonapride, 122*f*
 neuregulin, 59, 64*f*
 genes coding for, 63*f*
 and glutamate synapses strengthening, 66*f*
 and NMDA receptor regulation, 68*f*
 and NMDA regulation, 71
 and synapse formation, 62, 65*f*
 neurokinin antagonists, 203
 neuroleptosis, 30, 82, 83, 150
 neuroleptic-induced deficit syndrome, 84
 neuroleptic-induced tardive dyskinesia, 31
 neuroleptic malignant syndrome, 96
 neuroleptics, 83
 neurons,
 cell death,
 excitotoxic mechanism and, 58*f*
 glutamate activity and, 55
 preventing in schizophrenia, 194
 dopaminergic, 20–22
 sensitivity to calcium, 59*f*
 neuropsychological assessment batteries, 11
 neurotensin antagonists, 204
 neurotransmitters,
 of cortical arousal, 152*f*
 glutamate as, 33
 5HT₆ receptors and, 103*f*
 nicotinic partial agonists (NPA), 203
 nigrostriatal dopamine pathway, 26*f*, 31, 32*f*
 antipsychotic agent binding to postsynaptic
 D2 receptors, 112*f*
 and D2 antagonists, 86*f*
 dopamine output and, 120*f*, 132*f*
 and dopamine partial agonists (DPAs), 131*f*
 serotonin–dopamine interaction, 107*f*
 serotonin regulation of dopamine release,
 108*f*
 NMDA (N-methyl-d-aspartate) antagonists,
 194, 195*f*
 NMDA (N-methyl-d-aspartate) receptors, 40,
 40*f*, 41, 44*f*
 enhancement of activity, 198*f*
 excitation spectrum by glutamate, 57*f*
 genes affecting, 58
 and glutamate systems, 37, 38*f*

- NMDA (N-methyl-d-aspartate) receptors
(*Contd.*)
hypofunction, 200
hypofunction hypothesis of schizophrenia,
44*f*, 45*f*, 69*f*, 70*f*, 72*f*
and corticobrainstem glutamate pathways,
42–45
hypofunction in glutamatergic corticostriatal
and corticoaccumbens projections, 51*f*
long-term potentiation (LTP) triggered by,
66*f*
normal excitatory neurotransmission of, 56*f*
production, 37
regulation of corticocortical glutamate
pathways, 53*f*
requirements for active, 197, 197*f*
susceptibility gene regulation of, 71
synapses with, 67*f*
and synaptogenesis, 62
- norepinephrine (NE). *See also* serotonin
norepinephrine reuptake inhibitors
(SNRIs)
in arousal pathways, 150, 152*f*
5HT2C receptors and, 103*f*
- norepinephrine reuptake inhibition (NRI), 174*f*
- norepinephrine selective reuptake inhibitors
(NRIs), 202
- norepinephrine transporter (NET),
inhibition,
by norquetiapine, 169
- norfluoxetine, 159
- norquetiapine, 168, 168*f*
- NRA0562, 122*f*
- nucleus accumbens,
D2 receptor blockade in, 107
as pleasure center, 83
and schizophrenia symptoms, 16, 75, 76*f*
“number needed to harm”, 87, 171
- obesity,
5HT2C receptors and, 103*f*
atypical antipsychotic agents and, 137
blood pressure monitoring, 146
peptide treatments for, 204
serotonin receptors and, 99
- observation, for negative symptom
identification in schizophrenia, 6, 8*f*
- olanzapine, 157, 157*f*, 164, 184
5HT6-antagonist properties of, 201
and antagonism of muscarinic cholinergic
receptor, 146*f*
and cardiometabolic risk, 140*t*
as CYP 2D6 substrate, 158, 159*f*
and diabetes, 171
- M3 receptors blocked by, 146*f*
pharmacological icon, 165*f*
potency, and dissociation, 125
raising levels of, 160*f*
for sedation, 185
and weight gain risk, 140*t*
- OPC 4293, 129
- oppositional defiant disorder, 179
and schizophrenia symptoms, 15
- Org 24292, 200
Org 25271, 200
Org 25501, 200
Org 25573, 200
osonetant (SR142801), 204
- paliperidone, 158, 159*f*, 160*f*, 167, 183
pharmacological icon, 167*f*
and sedation, 186*f*
sedation risk with, 184
- parabrachial nucleus (PBN)
dopamine pathway from, 26*f*, 33
- paranoia, 78
- paranoid projection, 3
- paranoid psychosis, 3
drug-induced, 86
dopamine agonists for treatment, 21
nigrostriatal pathway dopamine deficiencies
and, 31, 32*f*
quetiapine for, 169
vs. antagonists, 132*f*
- perceptual distortions, 2
- periaqueductal gray matter,
dopamine pathway from, 26*f*, 33
- perospirone, 173
pharmacological icon, 173*f*
- perphenazine (Trilafon), 85*t*
- pharmacodynamics, 156
- pharmacokinetics, 156
- phencyclidine (PCP),
and schizophrenia symptoms, 43, 44, 194
- Pick's disease, cognitive symptoms, 13
- pimozide (Orap), 85*t*
- pipothiazine (Piportil), 85*t*
- pituitary
regulation of prolactin secretion, 116
SPA action in, 131
- pleasure
mesolimbic dopamine pathway role in, 26, 30
reduce ability to experience, 5
- pleasure center
nucleus accumbens as, 83
- PNU 9639/OSU 6162, 134*f*
- polypharmacy, 190, 192*f*
- Positive and Negative Syndrome Scale, 7*t*

- poststroke dementia, cognitive symptoms, 13
- pramlintide, 204
- prefrontal cortex,
 - 5HT_{2A} receptor activation, in schizophrenia, 114
 - fetal development, and schizophrenia, 57
 - and schizophrenia symptoms, 15, 75
 - SPA action in, 131
- presynaptic 5HT_{1A} receptors, 102*f*
- presynaptic 5HT_{1B/D} receptors, 101*f*
- presynaptic antagonists, 199*f*
- presynaptic D₂ receptors, 22, 23*f*, 24*f*
- procognitive agents, D₁-selective agonists as, 202
- prodrome
 - negative symptoms, 6, 10*f*
 - amisulpride and, 177
 - atypical antipsychotic agents and, 118*f*
 - clozapine and, 163
 - conventional antipsychotic agents and, 118*f*
 - elevation, 90
 - inhibiting release, 32
 - inhibition by dopamine, 117*f*
 - olanzapine and, 165
 - quetiapine and, 169
 - rise in levels, 88*f*
 - risperidone and, 167
 - secretion regulation, 116
 - serotonin stimulation of, 117*f*
 - zotepine and, 172
- Prolixin (fluphenazine), 85*t*
- protease inhibitors, 159
 - glutamate for biosynthesis, 33
- psychosis, 1
 - acute, ziprasidone for, 170
 - antipsychotic action to reduce symptoms, 179
 - as associated feature in disorders, 3*t*
 - disorders requiring presence as defining feature, 2, 2*t*
 - mesolimbic dopamine pathway role in, 26
 - positive symptoms, 5*t*
 - quetiapine for, 169
 - rebound, from discontinued clozapine, 185
 - psychotic depression, symptoms shared with schizophrenia, 12, 13*f*
- psychotic episode, 4
- psychotic illness
 - combination chemotherapies for, 204
 - misconceptions, 1
- pyramidal cells,
 - malfunctioning glutamate input into, 52
 - output and input, 49
- QTc prolongation, ziprasidone and, 171
- questioning, for negative symptom
 - identification in schizophrenia, 8*f*
- quetiapine, 136*f*, 158, 168, 183
 - 5HT₆-antagonist properties of, 201
 - binding properties, 168*f*
 - and cardiometabolic risk, 140*t*
 - and diabetes, 171
 - dosage with carbamazepine, 161*f*, 162
 - pharmacological icon, 168*f*
 - potency, and dissociation, 124
 - for sedation, 185
 - switching to non-sedating agent, 189
 - and weight gain risk, 140*t*
- rapid dissociation, 119, 121, 122*f*, 124*f*
- rapid “off” time, 119
- reasoning. *See also* cognitive functioning
 - distortions in schizophrenia, 78
- rebound psychosis, from discontinued clozapine, 185
- relapse,
 - after antipsychotic treatment, vs. side effects, 95
- remission
 - by schizophrenic patient, 54
- resentment, 3
- retardation, 3
- reward
 - blocking mechanisms, 84
 - in mesolimbic dopamine system, 90
 - mesolimbic dopamine pathway role in, 26, 30
- RGH188, 134*f*
- rimonabant, 203
- risperidone, 166, 183
 - and cardiometabolic risk, 140*t*
 - conversion to paliperidone, 159*f*, 160*f*
 - as CYP 2D6 substrate, 158, 159*f*
 - and diabetes, 171
 - pharmacological icon, 166*f*
 - potency, and dissociation, 124
 - raising levels of, 160*f*
 - and sedation, 184, 186*f*
 - for treating irritability, 181
 - and weight gain risk, 140*t*
- RGS4 (regulator of G-protein signaling), 71
 - genes for, 72*f*
- sarcosine, 196
- sarizotan (EMD128130), 134*f*, 202
- Scale for Assessment of Negative Symptoms, 7*t*
- scary faces, schizophrenic patient response to, 77*f*, 78
- Schedule for the Deficit Syndrome, 7*t*

- schizoaffective disorder,
 symptoms shared with schizophrenia, 12, 13*f*
- schizophrenia
 5HT2A receptors activation in prefrontal cortex, 114
 acquired vs. inherited, 56
 atypical antipsychotics to improve symptoms, 109
 best long-term outcomes, 154*f*, 155*f*
 bifeprunox for treating, 178
 cognitive symptoms, 13, 13*t*
 combination chemotherapies for, 204
 diagnosis, value of deconstructing, 18
 excitotoxicity and, 56, 57*f*
 fetal brain insult and, 57
 free radical scavengers, 196*f*
 genetic basis, 58
 glutamatergic treatments for, 196*f*
 ideal treatment of, 112
 integrated dopamine hypothesis, 33, 35*f*, 88*f*
 and dopamine partial agonists, 132*f*
 and hit-and-run actions, 127*f*
 and serotonin-dopamine antagonists, 121*f*
 mesocortical dopamine hypothesis of
 negative, cognitive, and affective symptoms of, 31*f*
 as more than psychosis, 3–7
 negative symptoms, 5, 5*t*, 6*t*
 causes, 14*f*
 observation to identify, 6, 8*f*
 primary and secondary, 7*t*
 in prodromal phase, 6, 10*f*
 questioning to identify, 8*f*
 reasons to measure, 7*t*
 scales for assessing, 7*t*
 shared with other disorders, 12
 neurodegenerative hypothesis, 54*f*, 52–56
 neurodevelopmental hypothesis, 62*f*, 64*f*–67*f*
 neuroimaging circuits in, 73
 neutral stimuli and, 78*f*
 NMDA receptor hypofunction hypothesis of, 44*f*, 45*f*, 42–45, 52, 69*f*, 70*f*, 72*f*
 patient responsiveness to antipsychotic treatment, 54
 positive and negative symptoms, 4*f*
 positive symptom pharmacy, 179, 180*f*
 positive symptoms, 4, 5*t*
 link to mesolimbic/nucleus accumbens area, 16
 shared with other disorders, 13*f*
 presymptomatic and prodromal treatment, 192, 193*f*
 progressive nature of, 52
 rapid clinical assessment, 9*t*
 risperidone effectiveness for, 167
 stages, 55*f*
 substance abuse incidence in, 30
 susceptibility genes for, 63*t*
 symptoms, 11*f*, 2–18, 75
 overlap, 12*f*
 shared with other illnesses, 12–18
 treatment, vs. disease treatment, 179
 ziprasidone for, 170
- schizophrenic patients
 life expectancy of, 4
 siblings of, 74
 n-back test in, 76*f*
 smoking and drug abuse by, 90, 203
 suicide in, 4
- sedation,
 antipsychotic agents and, 150–154
 avoiding, 152–153, 155*f*
 long-term avoidance, 153*f*
 quetiapine and, 169
 receptors mediating, 151*f*
 as short-term therapeutic tool, 152*f*
 vs. somnolence, 154*f*
 zotepine and, 172
- sedation pharmacy, 184, 186*f*
- seizures
 clozapine or zotepine and increased risk, 158, 164
 zotepine and, 172
- self-mutilation, 179
- Serentil (mesoridazine), 85*t*
- serial learning, impaired, in schizophrenia, 11
- d-serine, 195, 197, 197*f*
 production, 37, 38*f*, 39
- d-serine racemase, 39
- l-serine, glycine synthesis from, 39
- serotonin-2C antagonist, histamine-1 with, and appetite stimulation, 141*f*
- serotonin (5HT), 72*f*
 1A agonists or antagonists, 201
 effect on glutamate release, 115*f*
 5HT1D antagonist action by ziprasidone, 172
 5HT2A antagonist binding to 5HT2A receptor, and dopamine release, 112
 and D2 antagonists, 119
 hyperprolactinemia reduction, 116
 reduction of positive symptoms, 116*f*
 effect on glutamate release, 115*f*
 and positive symptoms improvement, 113–116
 5HT2A-selective antagonists/inverse agonists, 200
 agonists or antagonists, 201
 functions, 103*f*

- olanzapine and, 165
 - and weight gain, 137
- 5HT6 antagonists, physiological role, 201
- 5HT7 antagonists, 201
- 5HT21 receptors, agonism of, 135*f*
- dorsolateral prefrontal cortex regulation by, 19*f*
- interaction with dopamine, in nigrostriatal dopamine pathway, 107*f*, 111*f*
- production, 98*f*
- prolactin stimulation of, 117*f*
- regulation of dopamine release, 108*f*–110*f*
- synthesis and termination of action, 97
- termination of action, 99*f*
- serotonin agonists, and 5HT2A antagonists, 132
- serotonin-dopamine antagonists (SDA), 96, 97*f*, 121*f*, 180*f*
 - for aggression management, 181*f*
 - for cognitive function improvement, 182*f*
 - in development, 122*f*
 - for first-line treatment of schizophrenia positive symptoms, 179
 - integrated theory of schizophrenia and, 121*f*
 - and mesocortical dopamine pathway, 113*f*
 - for negative symptoms in schizophrenia, 182*f*
 - new options, 200
 - switching to DPA, 190*f*
- serotonin partial agonists (SPAs), 96, 136*f*
 - atypical antipsychotic agents and, 131
- serotonin receptors, 97, 100*f*, 105
 - 5HT1A and 5HT2A, 99
 - 5HT1A autoreceptors, 102*f*
 - 5HT1A receptors, 105*f*
 - 5HT1B/D autoreceptors, 101*f*
 - 5HT2A antagonist reduction of EPS, 105–107
 - 5HT2A receptors, 105, 105*f*, 106*f*
 - antagonist reduction of negative symptoms, 108–112
 - 5HT3 receptors, 103*f*
 - 5HT6 receptors, 103*f*
 - 5HT7 receptors, 103*f*
- postsynaptic, 97, 105
 - impact of, 98
 - possible functions, 103*f*
 - presynaptic, 97–105
- serotonin selective reuptake inhibitors (SSRIs), 110
 - fluvoxamine, 159, 200
- serotonin transporter (SERT), 97
 - gene for, 73*f*
- sertindole, 158, 173
 - 5HT6-antagonist properties of, 201
 - dosage with carbamazepine, 161*f*, 162
 - pharmacological icon, 174*f*
 - and QTc prolongation, 171
- siblings of schizophrenic patients, 74
 - n-back test in, 76*f*
- sigma-1 agonists/antagonists, 200
- “sigma enigma”, 200
- skeletal muscle, insulin resistance in, 141, 144*f*
- sleep
 - 5HT2A receptors and, 103*f*
 - quetiapine for improving, 168*f*
 - serotonin receptors and, 99
- SLV313, 129, 134*f*, 202
- SLV314, 129, 134*f*, 202
- SM13493/lurasidone, 122*f*
 - CYP450 1A2 and, 158, 158*f*
 - by schizophrenic patients, 90, 203
- somatodendritic autoreceptor, 98, 102*f*
- somatodendritic dopamine D2 receptors, 25*f*
- somnolence, vs. sedation, 154*f*
- spinophyllin, genes for, 73*f*
- SR 147778, 203
- SR 241586, 204
- SR141716 A, 203
- SR31742A, 200
- SSR 146977, 204
- SSR125047, 200
- SSR180711, 203
- SSR181507, 134*f*, 202
- SSR591813, 203
- Stahl, S.M., *Essential Psychopharmacology: The Prescriber's Guide*, 162, 163
- Stelazine (trifluoperazine), 85*t*
- striatum,
 - SPA action in, 131
- stroke, 180
 - excitotoxicity and, 56, 57*f*
- substance abuse. *See also specific substance types*
 - incidence in schizophrenia, 30
- substance P antagonists, 203
- substantia nigra, 31
 - in schizophrenic patients, 4
 - attempts, 179
 - clozapine to reduce, 164, 183, 184*f*
 - sulpiride (Dolmatil), 85*t*, 96, 129, 130, 134*f*, 135*f*, 177
 - clinical actions of, 125
 - pharmacological icon, 177*f*
 - superiority, attitude of, 3
- susceptibility genes, 58
 - for schizophrenia, 63*t*, 73
- switching antipsychotic agents, 185, 187*f*
 - process to avoid, 187*f*
- symptom domains, localization of, 15

- synapses,
 strength of, and survival or elimination, 67
 abnormal, 61
 genes causing, 65*f*, 66*f*
 from gene expression, 58
- talnetant, 204
- tandospirone, 201
- tardive dyskinesia, 86, 87*f*, 95, 123*f*
 clozapine and, 163
 neuroleptic-induced, 31
 reversal, 87
 from unwanted D2 receptor blockade, 136
- TC1827, 203
- tension, 14
- Tercian (cyamemazine), 85*t*, 96, 175
 pharmacological icon, 175*f*
- terminal autoreceptor, 98
- thalamic dopamine pathway, 33
- thalamocortical glutamate pathways, 43*f*, 46
 dopamine pathway to, 26*f*
 mesolimbic dopamine hyperactivity and, 50*f*
 sensory filter from GABA neurons, 46, 47*f*
 dopamine and, 48*f*
 sensory input inhibition from, 49*f*
- thioridazine (Mellaril), 85*t*
- thiothixene (Navane), 85*t*
- Thorazine (chlorpromazine), 82, 85*t*
- tics
 dopamine hyperactivity in nigrostriatal pathway and, 31, 32*f*
- TOH (tyrosine hydroxylase), 20, 20*f*
- tremor
 as antipsychotic side effect, 95
 nigrostriatal pathway dopamine deficiencies and, 31
- trifluoperazine (Stelazine), 85*t*
- triglycerides, elevated, atypical antipsychotic agents and, 144*f*
- tryptophan, 97, 98*f*
- tryptophan hydroxylase (TRY-OH), 97, 98*f*
- tuberoinfundibular dopamine pathway, 26*f*, 32, 32*f*
 and D2 antagonists, 88*f*
 dopamine output and, 120*f*, 132*f*
 hypoactivity of, 35*f*
- tyrosine, 20, 20*f*
- tyrosine hydroxylase (TOH), 20, 20*f*
 genes for, 73*f*
- vabicaserin, 201
- varenicline, 203
 dopamine pathway from, 26*f*, 33
- ventromedial prefrontal cortex (VMPFC),
 dopamine deficit in mesocortical projections to, 28
 mesocortical dopamine pathway to, 30*f*
 and schizophrenia symptoms, 15, 76*f*
- verbal abuse, 179
- verbal fluency, impaired, in schizophrenia, 11
- vesicular glutamate transporters (vGluT), 36*f*, 39, 40*f*
 dysbindin regulation of, 71
- vesicular monoamine transporters (VMATs),
 and dopamine, 22*f*
- violence, 10
- Vitamin E
 as free radical scavenger, 196*f*
- vomiting
 5HT₃ receptors and, 103*f*
 bifeprunox and, 178
 serotonin receptors and, 99
- waist circumference, monitoring, 146
- weight
 baseline measurement, 149*f*
 antipsychotic agents and, 143*f*
 aripiprazole and, 176
 atypical antipsychotic agents and, 137, 140*t*
 clozapine and, 164
 from histamine-1 receptor blockade, 95
 low risk antipsychotic agents, 140*t*
 monitoring, 150*f*
 olanzapine and, 165
 quetiapine and, 169
 ziprasidone and, 171
 zotepine and, 172
- worry, 14. *See also* anxiety
- Y931, 122*f*
- ziprasidone, 136*f*, 158, 170, 183
 with 5HT_{1D} antagonist actions, 172
 and cardiometabolic risk, 140*t*
 dosage with carbamazepine, 161*f*, 162
 pharmacological icon, 170*f*
 and sedation, 184, 186*f*
 and weight gain risk, 140*t*
- zotepine, 157, 157*f*, 158, 172
 5HT₆-antagonist properties of, 201
 binding properties, 172*f*
 dosage with carbamazepine, 161*f*, 162
 pharmacological icon, 172*f*
 and QTc prolongation, 171
 zuclopenthixol (Clopixol), 85*t*